An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL researchers.

As the sun dipped below the horizon, casting a warm glow over the streets of London, Sarah Thompson sat alone at her dining table, swirling her fork amidst a plate of uneaten greens. At 48, she found herself at a crossroads: two years of dieting had left her frustrated and yearning for a more effective solution. “My entire life has revolved around weight,” she confessed, her eyes glistening with unshed tears. “When I heard about the new weight-loss drugs, it felt like a beacon of hope.”

New research from University College London (UCL) confirms that Sarah’s desperation is not unique. Between early 2024 and early 2025, approximately 1.6 million adults in England, Wales, and Scotland turned to medications like Mounjaro and Wegovy for help with weight loss. The study, published in BMC Medicine and funded by Cancer Research UK, paints a vivid picture of a country grappling with obesity while displaying a growing interest in pharmacological solutions.

Heightened Interest Amidst Rising Obesity Rates

The UCL team analyzed data from 5,260 respondents, representative of the general population, and found that a staggering 4.9 million adults—nearly one in ten—either used a weight-loss drug in the past year or expressed interest in using one. Lead author Professor Sarah Jackson noted, “Our findings showcase an alarming trend where the desire for pharmaceutical interventions outpaces our healthcare system’s ability to provide equitable access.”

Among those engaged with weight-loss drugs, usage was distinctly gendered and age-determined:

• 4% of women reported using these drugs compared to just 1.7% of men.
• Usage peaked among those aged 45 to 55, with 4.2% reporting use.
• Psychological distress correlated with usage; 3.7% of those experiencing mental health challenges reported resorting to medications.

Demand Outstripping Availability

This surge in interest presents both opportunity and peril. With the NHS reportedly aiming to prescribe these drugs to 220,000 individuals over three years, a gap emerges between what people want and what is available. Professor Clare Llewellyn, a co-author on the study, stated, “These medications can play a crucial role in managing obesity, but widespread access is vital to address pre-existing health disparities.”

The statistics are telling. As the nation’s obesity rates climb, the market for these drugs continues to grow, yet approximately 15% of users are taking medications without formal approvals for weight loss, exposing themselves to potential risks. “While it’s essential to consider off-label use, we must emphasize the importance of medical supervision,” said Dr. Mark Hollis, a public health expert from Cambridge University. “Unfettered access without guidance may worsen rather than remedy health issues.”

The Personal Tug-of-War

The implications echo through personal stories like Sarah’s, who found herself captivated by the allure of quick results. “I heard about Mounjaro on social media,” she recalled. “It felt like the magic pill I’d been waiting for.” However, her enthusiasm is tinged with doubt. “What if this was just another empty promise?”

Similar sentiments are echoed in surveys. While 6.5% of respondents expressed future interest in weight-loss drugs, the allure is particularly strong among disadvantaged groups where obesity is prevalent. Sarah Harwood, a behavioral psychologist, suggests this can lead to unintended consequences: “The excitement over these drugs may lead individuals to undervalue the importance of holistic weight management approaches, including nutrition and physical activity.”

The Ethical Landscape

As pharmacies fill with these high-demand medications, ethical considerations regarding their accessibility become paramount. Mounjaro, priced around £200 a month, remains beyond the reach of many, creating a two-tier system where wealthier individuals can afford pharmaceutical solutions while others are left with limited options.

Jo Harby, Director of Health Information at Cancer Research UK, argues for a balanced approach, stating, “Obesity is a complex issue that relies on more than just medication. We must aim for a comprehensive support system that includes education and access to healthier lifestyles.”

The Road Ahead

The findings of this study are prompting calls for more nuanced and equitable public health policies. “Long-term studies are essential,” said Professor Jackson. “We need data that illuminate how these trends evolve and whether they serve genuine medical needs or contribute to the epidemic of needless drug dependency.”

As individuals like Sarah navigate their health journeys, blending new pharmaceutical options with lifestyle modifications, the UCL study highlights a crossroads: the growing desire for pharmacological solutions must be matched by public health strategies that ensure equitable access and informed usage.

In the battle against obesity, the path forward must integrate compassion, understanding, and a comprehensive approach to heling individuals navigate their unique health challenges. Sarah’s story is a poignant reminder that while new solutions are emerging, the dialogue surrounding access, equity, and genuine health needs must remain at the forefront of this ongoing conversation.

Source: www.ucl.ac.uk